Ms. Marie McDonald - 18 Mar 2026 Form 3 Insider Report for Telix Pharmaceuticals Ltd (TLX)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 20:48:38 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Genevieve Ryan, on behalf of Ms. Marie McDonald

Key filing fact

Ms. Marie McDonald filed Form 3 for Telix Pharmaceuticals Ltd (TLX) on 18 Mar 2026.

Key facts

  • This page summarizes Ms. Marie McDonald's Form 3 filing for Telix Pharmaceuticals Ltd (TLX).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 20:48.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002120369 Primary reporting owner

McDonald Marie Elizabeth

Relationship
Director
Address
C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
Signature
/s/ Genevieve Ryan, on behalf of Ms. Marie McDonald
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TLX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,719
Date
18 Mar 2026
Ownership
Netwealth Investments Limited
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Custodian for ordinary shares reported as indirectly held by Ms. McDonald.

SEC remarks

Ex. 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .